A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT
Stopped Based on other clinical trial results it was unlikely the study would meet the efficacy endpoints
Conditions
Interventions
- DRUG: rhGAD65
- DRUG: rhGAD65
- DRUG: Placebo
Sponsor
Diamyd Therapeutics AB